KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables - Other: 2009-2016

Historic Receivables - Other for Biomarin Pharmaceutical (BMRN) over the last 2 years, with Sep 2016 value amounting to $8.4 million.

  • Biomarin Pharmaceutical's Receivables - Other was N/A to $8.4 million in Q3 2016 from the same period last year, while for Sep 2016 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $116.5 million for FY2013, which is N/A change from last year.
  • Biomarin Pharmaceutical's Receivables - Other amounted to $8.4 million in Q3 2016, which was down 92.79% from $116.5 million recorded in Q4 2013.
  • Biomarin Pharmaceutical's Receivables - Other's 5-year high stood at $116.5 million during Q4 2013, with a 5-year trough of $6.8 million in Q1 2012.
  • For the 1-year period, Biomarin Pharmaceutical's Receivables - Other averaged around $8.4 million, with its median value being $8.4 million (2016).
  • Data for Biomarin Pharmaceutical's Receivables - Other shows a peak YoY surged of 111.90% (in 2012) over the last 5 years.
  • Quarterly analysis of 3 years shows Biomarin Pharmaceutical's Receivables - Other stood at $9.0 million in 2012, then followed by $116.5 million in 2013, then followed by $8.4 million in 2016.
  • Its Receivables - Other stands at $8.4 million for Q3 2016, versus $116.5 million for Q4 2013 and $9.0 million for Q3 2012.